Barclays Slashes Microsoft (MSFT) Target to $430—Time to Panic or Buy the Dip?
Barclays just took a cleaver to Microsoft’s price target—dropping it to $430 amid ’macro concerns’ (read: analysts covering their backs). The move raises eyebrows: is this a legit red flag or just another case of Wall Street playing musical chairs with targets? MSFT bulls argue Azure growth and AI bets remain solid, while bears whisper about slowing cloud momentum. Either way, the stock’s reaction will show who’s really paying attention—and who’s just chasing headlines like a day trader on espresso shots.
Source: ymgerman / iStock Editorial / Getty Images
Microsoft Bounces Back Amid Surging Market as Experts Slash Expectations
After months of stagnating and a near market crash, US stocks are finally starting to bounce back. The Dow jumped 400 points at the end of trading Wednesday. Moreover, the Nasdaq joined in on the gains, jumping 2.5% by the time the final bell rang. Yet, with the optimistic week ongoing, all eyes are fixed on where several stocks could go from here.
As per usual, the Magnificent 7 have dominated the discussions. With so many high-profile stocks with opportunities for increased gains, hitting on these mega-cap tech giants could be monumental. However, some analysts have lowered expectations on one company in particular, as Microsoft has seen its stock target cut to $430 by Barclays.
Analysts at the firm slashed the share price projection from $475, according to a recent report. Moreover, it has kept an overweight rating on the stock. They certainly aren’t alone, as BMO Capital also lowered its target to $470 from its previous $490 projection.
Microsoft shares ended Wednesday up 1.97%, reversing an 11% drop that has taken place over the last 6 months. Moreover, it holds a $480 median price target, up 28% from where it stands now. Altogether, it looks to have an optimistic outlook. According to CNN data, its high-end price projection sits at $600, showcasing 60% upside. Even on the low end, it has a $415 worst-case projection, still up 10% from its current $374 price.
